Search

Your search keyword '"Ana Ascaso-del-Rio"' showing total 3 results
Start Over Author "Ana Ascaso-del-Rio"
3 results on '"Ana Ascaso-del-Rio"'

1. Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

Author

Javier García-Pérez, Alberto M. Borobia, Mayte Pérez-Olmeda, Antonio Portolés, Luis Castaño, Magdalena Campins-Artí, María Jesús Bertrán, Mercedes Bermejo, José Ramón Arribas, Andrea López, Ana Ascaso-del-Rio, Eunate Arana-Arri, Inmaculada Fuentes Camps, Anna Vilella, Almudena Cascajero, María Teresa García-Morales, María Castillo de la Osa, Carla Pérez Ingidua, David Lora, Paloma Jiménez-Santana, Silvia Pino-Rosa, Agustín Gómez de la Cámara, Erick De La Torre-Tarazona, Esther Calonge, Raquel Cruces, Cristóbal Belda-Iniesta, José Alcamí, Jesús Frías, Antonio J. Carcas, Francisco Díez-Fuertes, Lucía Díaz García, Elena Ramírez García, Enrique Seco Meseguer, Stefan Mark Stewart Balbàs, Alicia Marín Candón, Irene García García, Mikel Urroz Elizalde, Paula de la Rosa, Marta Sanz García, Cristina López Crespo, Vega Mauleón Martínez, Raquel de Madariaga Castell, Laura Vitón Vara, Rocío Prieto-Pérez, Emilio Vargas-Castrillón, Leonor Laredo, Ouhao Zhu-Huang, Teresa Iglesias, Natale Imaz-Ayo, Susana Meijide, Aitor García de Vicuña, Ana Santorcuato, Iraide Exposito, Sara de Benito, Alazne Bustinza, Mikel Gallego, Dolores García-Vázquez, Ana Belén de la Hoz, Gustavo Pérez-Nanclares, Josu Aurrekoetxea, Ines Urrutia, Rosa Martínez-Salazar, Janire Orcajo, Begoña Calvo, June Corcuera, Olaia Velasco, Anibal Aguayo, Xavier Martínez-Gómez, Susana Otero-Romero, Lluis Armadans, Blanca Borras-Bermejo, Oleguer Parés, Sonia Uriona, José Ángel Rodrigo Pendás, Cesar Llorente, José Santos, Laia Pinós, Lina Camacho, Judith Riera, Carla Sans, Antonia Agustí, Carmen Altadill, Carla Aguilar Blancafort, Gisela Gili Serrat, Aitana Plaza, Anna Feliu Prius, Maria Margarita Torrens, Esther Palacio, Gloria Torres, Julia Calonge, Elena Ballarin Alins, Eulàlia Pérez-Esquirol, Lourdes Vendrell Bosch, Marta Aldea, Eugènia Mellado, Ma Ángeles Marcos, Marta Tortajada, Lourdes E. Barón-Mira, Laura Granés, Sulayman Lazaar, Sara Herranz, Montserrat Malet, Sebastiana Quesada, Anna Llupià, Victoria Olivé, Antoni Trilla, Begoña Gómez, Elisenda González, Sheila Romero, Francisco Javier Gámez, Cristina Casals, Laura Burunat, Juan José Castelló, Patricia Fernández, Josep Lluís Bedini, Jordi Vila, Juan Carlos Hurtado, Isabel Jado, Giovanni Fedele, Concepción Perea, Mónica González, Isabel Grajera, María Ángeles Murillo, Pilar Balfagón, Irene Díaz-Marín, and Gema González-Pardo

Subjects
Immunology, Immune response, Science
Abstract

Summary: CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months. The third vaccine dose of mRNA-1273 in naive participants previously vaccinated with ChAdOx1-S/BNT162b2 regimen reached higher neutralizing antibodies titers against the variants of concern Delta and BA.1 lineage of Omicron compared with those receiving a third dose of BNT162b2 at day 28. These differences between BNT162b2 and mRNA-1273 arms were observed against the ancestral variant G614 at day 90. Suboptimal neutralizing response was observed against BQ.1.1, XBB.1.5/XBB.1.9, and JN.1 in a relevant proportion of individuals 180 days after the third dose, even after asymptomatic Omicron breakthrough infections. EudraCT (2021-001978-37); ClinicalTrials.gov (NCT04860739).

Published
2024
Full Text
View/download PDF

2. Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study

Author

Ana Ascaso-del-Rio, Javier García-Pérez, Mayte Pérez-Olmeda, Eunate Arana-Arri, Itziar Vergara, Carla Pérez-Ingidua, Mercedes Bermejo, María Castillo de la Osa, Natale Imaz-Ayo, Ioana Riaño Fernández, Oliver Astasio González, Francisco Díez-Fuertes, Susana Meijide, Julio Arrizabalaga, Lourdes Hernández Gutiérrez, Humberto Erick de la Torre-Tarazona, Alberto Mariano Lázaro, Emilio Vargas-Castrillón, José Alcamí, and Antonio Portolés

Subjects
COVID-19 vaccines, mRNA vaccines, Heterologous vaccination, BNT162b2, CVnCoV, Fourth dose, Medicine (General), R5-920
Abstract

Summary: Background: There is no evidence to date on immunogenic response among individuals who participated in clinical trials of COVID-19 experimental vaccines redirected to standard national vaccination regimens. Methods: This multicentre, prospective controlled cohort study included subjects who received a COVID-19 experimental vaccine (CVnCoV)(test group, TG) - and unvaccinated subjects (control group, CG), selected among individuals to be vaccinated according to the Spanish vaccination program. All study subjects received BNT162b2 as a standard national vaccination schedule, except 8 (from CG) who received mRNA-1273 and were excluded from immunogenicity analyses. Anti-RBD antibodies level and neutralising titres (NT50) against G614, Beta, Mu, Delta and Omicron variants were analysed. Reactogenicity was also assessed. Findings: 130 participants (TG:92; CG:38) completed standard vaccination. In TG, median (IQR) of anti-RBD antibodies after first BNT162b2 dose were 10740·0 BAU/mL (4466·0-12500) compared to 29·8 BAU/mL (14·5-47·8) in CG (p

Published
2022
Full Text
View/download PDF

3. Monitoring of PIK3CA and ESR1 mutations in circulating tumor DNA as predictive and prognostic biomarkers in patients with endocrine-resistant ER+/HER2- advanced breast cancer

Author

Vanesa García-Barberán, Jesús Fuentes Antrás, Irene Gonzalo, José A. García-Sáenz, Trinidad Caldés, Igor López-Cade, Alberto Ocaña, Ana Ascaso del Rio, Oskia Bueno, Fernando Moreno, Alejandro Pascual, and Carmen Ramírez-Ruda

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Standard of care, business.industry, Advanced breast, Cancer, Estrogen receptor, medicine.disease, Circulating tumor DNA, Internal medicine, medicine, Endocrine system, In patient, business, Estrogen receptor alpha
Abstract

e13045 Background: Combination therapeutic strategies including CDK4/6 inhibitors and an endocrine backbone are the standard of care of treatment for patients with estrogen receptor positive (ER+)/HER2- advanced breast cancer (ABC). Endocrine agents mainly include aromatase inhibitors, which target ER-driven transcription, and fulvestrant, which functions as ER antagonist. PI3K-AKT-mTOR is a key point of resistance to endocrine therapy, activated in 40% of these patients by mutations concentrated in critical regions of PIK3CA, coding for the p110 catalytic subunit α of PI3K. Additionally, 30% of patients previously exposed to non-steroidal aromatase inhibitors develop mutations in the ligand binding domain of ESR1, causing endocrine resistance by constitutive activation of the ER. Furthermore, metastasis and primary tumors may show a highly heterogenous mutational landscape. Monitoring the dynamic changes of these mutations in ctDNA may provide a non-invasive, real-time and accessible tool to convey predictive/prognostic information and guide decisions on sequential endocrine therapies. Methods: Pre-planned interim analysis results of an observational, prospective cohort pilot study to assess the predictive and prognostic value of monitoring PIK3CA and ESR1 mutations in ctDNA of patients with endocrine-resistant ER+/HER2- ABC. We have studied longitudinal liquid biopsies from 30 patients using digital PCR to interrogate PIK3CA mutations (H1047R / E545K) and ESR1 mutations (D538G / Y537S). Blood samples were drawn at the time of progression to endocrine therapy, at 8 weeks of subsequent endocrine line and at new progression. This exploratory analysis will provide preliminary data on clinical homogeneity, treatment regimens, median follow-up and progression-free survival, mutation incidence and intraindividual variation of mutant allele frequency and copy number. The percentage of progressors at 24 weeks of follow-up according to the mutational status will be evaluated by using the Fisher’s exact test. The predictive potential of ctDNA biomarkers will be characterized by ROC curve analysis. Tracking ctDNA mutations to predict endocrine resistance in a real-world setting represents a critical step towards precision medicine in oncology.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results